The Wiley Online Library has indexed a peer-reviewed review titled "Skin and gut microbiome in atopic dermatitis: Mechanisms and therapeutic opportunities," framing cutaneous and gastrointestinal microbiome data as one translational field.

The title commits the authors to a unified scope. Atopic dermatitis is examined through both skin and gut axes, with mechanisms paired to therapeutic opportunities rather than treated as separate literatures.

Why this synthesis now?

Atopic dermatitis drives one of dermatology's most active translational pipelines. WHO-cited figures place pediatric prevalence near 15-20% and adult prevalence around 2-3% in high-income settings, though diagnostic criteria vary by cohort. Lesional skin consistently shifts toward Staphylococcus aureus dominance and away from commensal diversity, a pattern tied to disease severity in multiple cohorts.

Infant stool composition in the first year has tracked later AD diagnosis in cohorts from Canada, Sweden, and the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC). Meta-analyses of pediatric probiotic trials report modest effects on AD incidence and severity, with Lactobacillus and Bifidobacterium strains most often tested. The NIAID's Roseomonas mucosa program, run through investigator Ian Myles, published phase 2 data in JCI Insight in 2021 after applying a cultured commensal isolate to adult and pediatric AD lesions.

What does the therapeutic pipeline look like?

Dupilumab, the IL-4 receptor alpha blocker, won FDA approval in March 2017 for moderate-to-severe adult AD and has since expanded across pediatric age groups. Tralokinumab and lebrikizumab followed as direct IL-13 antagonists. The JAK inhibitor class — topical ruxolitinib plus oral upadacitinib, abrocitinib, and baricitinib — reshaped the rapid-response toolkit for refractory disease.

Microbiome-targeted strategies now sit beside those mechanisms. Siol Therapeutics and DermBiont are moving engineered consortia through early clinical work.

What the title tells clinicians about the scope

Reviewers labeled the piece "Skin and gut microbiome in atopic dermatitis: Mechanisms and therapeutic opportunities" — a verb pair that signals intent to bridge basic science and clinic in one document. The "skin and gut" pairing also marks an editorial maturation point: a decade ago the two literatures appeared in separate journals under separate research groups. Wiley's indexing of a unified review suggests the publisher now treats the axis as one field.

Such syntheses carry downstream effects. Payers may weigh probiotic regimens for reimbursement decisions; clinicians may use these reviews to prioritize stool or skin sampling in workups; trial sponsors may mine the cited literature for novel targets.

What dermatologists can verify from the Wiley index alone

Limited. The Wiley Online Library listing surfaces the article title and a publisher link but no abstract, no author byline, no host journal, and no DOI in the source provided. Dermatology teams will need institutional access to evaluate inclusion criteria, primary studies cited, and specific conclusions on which interventions deserve clinical priority. The indexed status does confirm peer-review clearance and entry into the citable record.

What's next for the skin-gut review lane?

Whether follow-on syntheses arrive from the British Journal of Dermatology, the Journal of the European Academy of Dermatology and Venereology, and Experimental Dermatology, all regular outlets in this niche. Skin-gut axis reviews now appear monthly across the dermatology literature, and that crowded lane will reward sharp differentiation on probiotic strain selection, prebiotic dosing, and topical commensal candidates.